A global phase 3 trial known as QWINT-1 demonstrated that the investigational basal insulin efsitora is as effective as daily glargine for managing blood glucose levels in insulin-naive adults with type 2 diabetes. Over 800 participants were involved, with HbA1c levels decreasing similarly in both groups after 52 weeks. Efsitora offered a lower incidence of severe hypoglycemia and required a lower average insulin dose, making it a promising once-weekly alternative to daily injections. Led by Dr. Julio Rosenstock, the results were presented at the ADA's 85th Scientific Sessions.

Source: The New England Journal of Medicine